Company profile: Equillium
1.1 - Company Overview
Company description
- Provider of therapeutics for autoimmune and inflammatory disorders, including itolizumab, a clinical-stage monoclonal antibody targeting the CD6-ALCAM pathway; EQ101, a tri-specific cytokine inhibitor of IL-2/IL-9/IL-15 in Phase 2 for alopecia areata; EQ302, an oral bi-specific inhibitor of IL-15/IL-21 in pre-clinical; and a multi-cytokine platform generating composite peptides to selectively block key cytokines at shared receptors.
Products and services
- Multi-Cytokine Platform: Composite peptide-based platform that generates assemblies selectively blocking key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies
- Itolizumab: Clinical-stage monoclonal antibody targeting the CD6‑ALCAM signaling axis, engineered to downregulate pathogenic T effector cells while preserving T regulatory cells for autoimmune and inflammatory indications
- EQ101: Phase 2 tri-specific cytokine inhibitor targeting IL‑2, IL‑9, and IL‑15 for alopecia areata, created to concurrently inhibit these cytokines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Equillium
ImmuPharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuPharma company profile →
Bryn Pharma
HQ: United States
Website
- Description: Provider of nasal-based epinephrine for anaphylaxis, including NDS1C, a needle-free, easy-to-use epinephrine nasal spray for the treatment of anaphylaxis. Also offers a Clinical Development Program focused on demonstrating the pharmacokinetic parameters and safety of NDS1C compared to the 0.3 mg IM epinephrine autoinjector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bryn Pharma company profile →
One Lambda
HQ: United States
Website
- Description: Provider of histocompatibility (HLA) typing tests using serological and molecular technologies, and manufacturer of antibody detection products, laboratory instrumentation, and computer software used to simplify and automate testing procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full One Lambda company profile →
Fresh Tracks Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical therapeutics for autoimmune, inflammatory, and debilitating diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fresh Tracks Therapeutics company profile →
Eleusis
HQ: United Kingdom
Website
- Description: Provider of clinical-stage psychedelic-based therapeutics and care delivery solutions, including ELE-Psilo, an investigational IV psilocin candidate for major depressive disorder; a platform for screening, treatment, monitoring, and continuing care to enhance safety, personalization, and accessibility; clinic operations via Andala providing access to psychiatric drug therapies; and discovery programs for anti-inflammatory, neuroprotective, and other psychiatric and non-psychiatric medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleusis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Equillium
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Equillium
2.2 - Growth funds investing in similar companies to Equillium
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Equillium
4.2 - Public trading comparable groups for Equillium
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →